Xin Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Placebo Controlled

Bipolar Disorder

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS drugs 38 (1) (2024)
Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS drugs 38 (1) (2024)
Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS drugs 38 (1) (2024)
Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS drugs (2024)
Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS drugs 38 (1) (2024)
Qian Li, Xin Li, Chong Ye, Miaomiao Jia, Tian-Mei Si
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis. CNS drugs (2023)